首页> 外国专利> THE MINIMAL PLASMID-BASED SYSTEM FOR GENERATION OF INFECTIOUS NEGATIVE STRANDED RNA OF VIRUSES FROM THE CLONED VIRUS cDNA, THE HOST CELL, CONTAINING THE PLASMID-BASED SYSTEM, THE METHOD FOR PRODUCTION OF INFECTIOUS NEGATIVE STRANDED RNA OF VIRUS AND THE METHOD FOR VACCINATION OF A PERSON AGAINST INFECTION OF NEGATIVE STRANDED RNA VIRUS

THE MINIMAL PLASMID-BASED SYSTEM FOR GENERATION OF INFECTIOUS NEGATIVE STRANDED RNA OF VIRUSES FROM THE CLONED VIRUS cDNA, THE HOST CELL, CONTAINING THE PLASMID-BASED SYSTEM, THE METHOD FOR PRODUCTION OF INFECTIOUS NEGATIVE STRANDED RNA OF VIRUS AND THE METHOD FOR VACCINATION OF A PERSON AGAINST INFECTION OF NEGATIVE STRANDED RNA VIRUS

机译:从克隆的病毒cDNA产生病毒的阴性阴性链RNA的最小基于质粒的系统,宿主细胞,包括基于质粒的系统,病毒的感染性阴性链RNA的生产方法和疫苗的疫苗接种方法感染负链式RNA病毒的人

摘要

The present invention is based on the development of a dual promoter system (preferably a RNA l - pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used lo synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassorlant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by contransfeclion of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
机译:本发明基于用于病毒RNA的有效细胞内合成的双启动子系统(优选为RNA 1-pol II系统)的开发。所得的基于最小质粒的系统可用于合成任何RNA病毒,优选具有负单链RNA基因组的病毒。当将系统的质粒引入合适的宿主细胞中时,产生系统的病毒产物。该系统的一种应用是生产减毒的,重新结合的流感病毒,用作疫苗中的抗原。通过质粒的转化产生的重配病毒可以包含编码来自目前正在感染人群的流感病毒的表面糖蛋白血凝素和神经氨酸酶的基因以及来自减毒流感病毒的内部基因。本发明的一个优点是它的通用性。该系统可以快速轻松地用于合成任何RNA病毒的减毒版。本发明产生的减毒或灭活的RNA病毒可以通过包括鼻内或肌内在内的几种途径中的任何一种给予需要疫苗接种的患者。

著录项

  • 公开/公告号UA84254C2

    专利类型

  • 公开/公告日2008-10-10

    原文格式PDF

  • 申请/专利权人 ST.JUDE CHILDRENS RESEARCH HOSPITAL;

    申请/专利号UA20020108499

  • 发明设计人 HOFFMANN ERICH;

    申请日2001-04-27

  • 分类号C12N15/09;C12N15/85;A61K39/145;A61P31/14;A61P31/16;C07K14/11;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N7/04;C12N15/44;

  • 国家 UA

  • 入库时间 2022-08-21 20:05:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号